Navigation Links
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Date:6/16/2011

SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab ("FPD-R") replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma ("INHL").

The Phase I-II study results showed that the FPD-R regimen was highly active in patients with relapsed or refractory INHL and produced complete responses ("CR") in 63% of patients with an overall response rate ("ORR") of 89%. Responses were long lasting for a median of 23 months with the longest responding patient in remission longer than 40 months, with an estimated 92% survival rate at three years. The primary side effects were hematologic with 89% of patients developing grade 3-4 neutropenia, which was managed with growth factor administration. No patient developed congestive heart failure with no grade 3-4 cardiac side effects observed. The authors concluded the FPD-R regimen was well-tolerated and highly active in patients with relapsed or refractory INHL.

"This study further adds to the evidence of substantial anti-tumor activity for pixantrone in late stage lymphoid malignancies," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "Of interest, of the 14 patients who were treated at M.D. Anderson Cancer Center, six who obtained a complete remission and did not have a stem-cell transplant remain in complete remission 55 to 83 months after completing therapy. Seven went on to receive a stem-cell transplant and six remain in remission. The high and durable complete response rate in this study indicates that additional clinical trials in relapsed or refractory INHL are warranted."

The publication is available at

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
3. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
4. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
5. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... th Annual Canaccord|Genuity Growth Conference in ... and CEO, William C. Taylor , President and ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical ... cell therapies, announced today that RepliCel,s CEO, David Hall ... Minneapolis, Minnesota on August 5 th ... RepliCel,s 18-month milestones including CE Mark for its RCI-02 dermal ... data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Inc ., has reported a smaller net loss of $5.2 million, ... molecular diagnostic revenue during the third quarter of 2006. , ,Third ... loss of $7.4 million, or 18 cents per share, for the ... company's third-quarter net loss improved 37 percent from its pro forma ...
... United States economy is cooling off just a bit, but ... not one of them, according to venture investment trackers. ... the third quarter of 2006, which represents a decline in ... PricewaterhouseCoopers and the National Venture Capital Association ...
... you follow Wisconsin's race for governor only by watching ... about gun control, the death penalty, abortion rights, stem ... gay marriage. , ,But when you spend time talking ... them, you get a dramatically different picture. Their priorities ...
Cached Biology Technology:Third Wave reports $5.2M third quarter loss 2Venture capital above $6B for third straight quarter 2Venture capital above $6B for third straight quarter 3What citizens don't ask political candidates 2What citizens don't ask political candidates 3
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... New research published in the international journal Neurobiology ... that being physically fit helps the brain function at ... for Medical Research Senior Scholar, Poulin finds that physical ... a result, cognitive abilities. "Being sedentary is now ...
... A study by researchers at the UC Davis M.I.N.D. Institute ... number children born in California with autism since 1990 cannot ... diagnosed or counted and the trend shows no sign ... the journal Epidemiology , results from the study also ...
... an international journal that publishes original research contributions ... entomology, plant pathology, virology, nematology and weed sciences, ... Emphasis is on new approaches in the control ... also publishes invited reviews, research notes and book ...
Cached Biology News:Research finds older women who are more physically fit have better cognitive function 2Study shows California's autism increase not due to better counting, diagnosis 2Study shows California's autism increase not due to better counting, diagnosis 3Springer expands its portfolio in plant sciences with Phytoparasitica 2
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: